ARCH-backed SciNeuro kicks off search for CNS autoantibodies with new deal; Merck + Gilead announce PhII trial for HIV combo

From the very beginning at SciNeuro, CEO Min Li has envisioned a mix of licensing deals and scientific efforts to replicate the breakout success of China’s oncology companies in neuroscience.

The GlaxoSmithKline vet has now inked a deal that somewhat straddles the line between the two strategies.

Teaming up...

Click to view original post